Combined Umbilical Cord MSC and Liraglutide Therapy Hypothesized to Improve Type 2 Diabetes Outcomes
Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus
Abstract
Liraglutide and umbilical cord mesenchymal stem cells are hypothesized to improve type 2 diabetes by enhancing beta-cell function and survival for better glucose control.
TitrateLab articles covering Liraglutide
Written by TitrateLab, separately from the study summarized above.
